Why Valeant Pharmaceuticals Intl Inc. Shares Surged as Much as 17% on Monday

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) shares soared after the company announced Michael Pearson will be stepping down.

| More on:
The Motley Fool

On March 21, there were more developments in the Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) saga.

Most notably, the company announced that CEO Michael Pearson will be stepping down as soon as a successor is found. In addition, activist investor Bill Ackman, head of Pershing Square Capital Management, has now joined the board of directors. And to top it all off, Valeant blamed its past financial misstatements on former CFO Howard Schiller and asked him to resign from the board of directors. Yet he has refused to do so.

While these developments may look like signs of chaos, investors reacted warmly to the news, sending Valeant’s shares up by as much as 17%. So why exactly did Valeant’s shares increase, and what does this news mean for the company in the long term?

Michael Pearson’s departure

Michael Pearson has been the face of Valeant’s rise as well as its fall. It was he who moved the company from the United States to Canada primarily for tax reasons. It was he who slashed Valeant’s R&D spending in favour of an acquisition-based model. And as the company finds itself in a downward spiral, he is at the centre of it all.

Up until March he was still held in very high regard. When the Philidor story dominated headlines, Mr. Ackman reiterated his support for Mr. Pearson. Then when Mr. Pearson had to step down at the end of 2015 (for health-related reasons), Valeant’s share price fell. More recently, Nomura Securities analyst Shibani Malhotra said Valeant would lose its competitive advantage if Mr. Pearson stepped down.

But that all changed when Valeant lowered its 2016 guidance on March 14. Now there’s a sense that the company has no idea what it’s doing, which, of course, reflects badly on the CEO. So it’s no surprise that his departure is being received well.

Bill Ackman’s presence

Not unlike Mr. Pearson, Bill Ackman is another public figure whose reputation has taken a dramatic turn for the worse.

Long known as one of Wall Street’s best activist investors, Mr. Ackman has had some remarkable successes; for example, he initiated the turnaround at Canadian Pacific Railway Limited, which has been a tremendous win for shareholders of that company.

But more recently, the story has been very different. When Valeant started running into trouble, he increased his stake, saying his biggest regret was that he wasn’t in a position to buy more shares. He also said that the company’s biggest problem was poor communication. During a conference call, he even predicted that Valeant’s shares would reach US$448 by 2019.

Yet Mr. Ackman still is held in high regard, so his decision to join the board may be viewed as a small positive.

Howard Schiller

It may seem unfair that Mr. Schiller is being made the scapegoat, since he stepped in as interim-CEO during a very difficult time. Then again, he was CFO at a time when the company misstated its financials.

In any case, this controversy is really more of a side story. Mr. Pearson’s departure was certainly the main reason Valeant’s share price increased, and Mr. Ackman’s increased involvement was likely a factor as well. We’ll have to wait and see how this all plays out.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Benjamin Sinclair has no position in any stocks mentioned.  Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

Nuclear power station cooling tower
Energy Stocks

Why Shares of Cameco Are Powering Higher

Cameco (TSX:CCO) shares have surged more than 400% in the last five years alone, with more growth on the way.

Read more »

A bull outlined against a field
Stocks for Beginners

Bull Market Buys: 2 TSX Stocks to Own for the Long Run

Are you looking for stocks that could see a bull run for decades ahead? Here are two top TSX stocks…

Read more »

financial freedom sign
Dividend Stocks

Million-Dollar TFSA: 1 Way to Achieve to 7-Figure Wealth

Achieving seven-figure TFSA wealth is doable with two large-cap, high-yield dividend stocks.

Read more »

analyze data
Dividend Stocks

How Much Will Manulife Financial Pay in Dividends This Year?

Manulife stock's dividend should be safe and the stock appears to be fairly valued.

Read more »

food restaurants
Dividend Stocks

Better Stock to Buy Now: Tim Hortons or Starbucks?

Starbucks and Restaurant Brands International are two blue-chip dividend stocks that trade at a discount to consensus price targets.

Read more »

Diggers and trucks in a coal mine
Metals and Mining Stocks

1 Canadian Mining Stock Worth a Long-Term Investment

Cameco (TSX:CCO) stock could be a great long-term investment for Canadian growth seekers.

Read more »

Pot stocks are a riskier investment
Investing

Could Investing $10,000 in Aurora Cannabis Stock Make You a Millionaire?

Let's dive into whether Aurora Cannabis (TSX:ACB) could be a potential millionaire-maker stock, or a dud, over the long term.

Read more »

stock analysis
Energy Stocks

Is Enbridge Stock a Good Buy in May 2024?

Boasting high-yielding dividends and a stable underlying business, Enbridge (TSX:ENB) might be a great buy for your self-directed investment portfolio…

Read more »